文献速递乳腺癌

对新辅助全身治疗卓越应答的侵袭性乳腺癌患者免除乳腺手术:一项多中心、单臂、2期试验

Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2022-10-25

这项在美国七中心开展的多中心单臂2期试验,纳入50例新辅助全身治疗后影像引导VACB证实病理完全缓解的早期三阴性或HER2阳性乳腺癌患者,免除乳腺手术仅接受全乳放疗。中位随访26.4个月,31例VACB证实病理完全缓解者无同侧乳腺肿瘤复发,未见严重活检相关不良事件或治疗相关死亡;作者认为该策略可行但需进一步前瞻性临床试验。

要点

  • 新辅助全身治疗后经9G影像引导VACB证实病理完全缓解的早期三阴性或HER2阳性乳腺癌患者,可免除乳腺手术仅接受全乳放疗。
  • 50例入组患者中VACB证实病理完全缓解31例(62%),中位随访26.4个月无同侧乳腺肿瘤复发。
  • 未发生严重活检相关不良事件或治疗相关死亡,作者认为该策略可行但需进一步前瞻性临床试验。

核心结论

  • 对经影像引导VACB证实新辅助全身治疗后病理完全缓解的高度选择患者,免除乳腺手术是可行的且早期结果令人鼓舞,但还需进一步前瞻性临床试验评估该策略。

研究设计与样本

  • 多中心、单臂、2期试验,在美国七个中心开展,研究注册号NCT02945579。
  • 纳入年龄40岁及以上、非妊娠、单中心性cT1-2N0-1M0三阴性或HER2阳性乳腺癌、临床标准新辅助全身治疗后影像学残留乳腺病灶小于2 cm的女性。
  • 患者接受9G影像引导VACB对瘤床取一次活检(至少12条组织);若无浸润性或原位病变,则免除乳腺手术并接受标准全乳放疗(40 Gy分15次或50 Gy分25次)加推量(14 Gy分7次)。
  • 主要结局为按方案人群用Kaplan-Meier法确定的活检证实的同侧乳腺肿瘤复发率;安全性在所有接受VACB的患者中评估。

主要发现

  • 2017年3月6日至2021年11月9日,58例患者同意参与,其中4例(7%)不符合最终纳入标准、4例(7%)撤回知情同意,最终50例入组并接受新辅助全身治疗后VACB。
  • 入组患者中位年龄62岁(IQR 55-77);21例(42%)为三阴性乳腺癌,29例(58%)为HER2阳性乳腺癌。
  • VACB在31例患者中确定病理完全缓解(62% [95% CI 47.2-75.4])。
  • 中位随访26.4个月(IQR 15.2-39.6),这31例患者中无同侧乳腺肿瘤复发。
  • 未发生严重活检相关不良事件或治疗相关死亡。

临床怎么用

  • 作者认为,对经影像引导VACB证实新辅助全身治疗后病理完全缓解的高度选择患者,免除乳腺手术是可行的且早期结果令人鼓舞,但还需进一步前瞻性临床试验评估该策略。

局限性

  • 作者指出还需进一步前瞻性临床试验评估该策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant systemic therapy (NST) for triple-negative breast cancer and HER2-positive breast cancer yields a pathological complete response in approximately 60% of patients. A pathological complete response to NST predicts an excellent prognosis and can be accurately determined by percutaneous image-guided vacuum-assisted core biopsy (VACB). We evaluated radiotherapy alone, without breast surgery, in patients with early-stage triple-negative breast cancer or HER2-positive breast cancer treated with NST who had an image-guided VACB-determined pathological complete response. METHODS: This multicentre, single-arm, phase 2 trial was done in seven centres in the USA. Women aged 40 years or older who were not pregnant with unicentric cT1-2N0-1M0 triple-negative breast cancer or HER2-positive breast cancer and a residual breast lesion less than 2 cm on imaging after clinically standard NST were eligible for inclusion. Patients had one biopsy (minimum of 12 cores) obtained by 9G image-guided VACB of the tumour bed. If no invasive or in-situ disease was identified, breast surgery was omitted, and patients underwent standard whole-breast radiotherapy (40 Gy in 15 fractions or 50 Gy in 25 fractions) plus a boost (14 Gy in seven fractions). The primary outcome was the biopsy-confirmed ipsilateral breast tumour recurrence rate determined using the Kaplan-Meier method assessed in the per-protocol population. Safety was assessed in all patients who received VACB. This study has completed accrual and is registered with ClinicalTrials.gov, NCT02945579. FINDINGS: Between March 6, 2017, and Nov 9, 2021, 58 patients consented to participate; however, four (7%) did not meet final inclusion criteria and four (7%) withdrew consent. 50 patients were enrolled and underwent VACB following NST. The median age of the enrolled patients was 62 years (IQR 55-77); 21 (42%) patients had triple-negative breast cancer and 29 (58%) had HER2-positive breast cancer. VACB identified a pathological complete response in 31 patients (62% [95% CI 47·2-75·4). At a median follow-up of 26·4 months (IQR 15·2-39·6), no ipsilateral breast tumour recurrences occurred in these 31 patients. No serious biopsy-related adverse events or treatment-related deaths occurred. INTERPRETATION: Eliminating breast surgery in highly selected patients with an image-guided VACB-determined pathological complete response following NST is feasible with promising early results; however, additional prospective clinical trials evaluating this approach are needed. FUNDING: US National Cancer Institute (National Institutes of Health).

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kuerer HM, Smith BD, Krishnamurthy S, et al. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022. PMID: 36306810. doi:10.1016/S1470-2045(22)00613-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。